RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01252251
First received: December 1, 2010
Last updated: July 21, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2016
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)